Heartbeam (BEAT) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
12 Nov, 2026Platform and cleared use
Cable-free, card-sized system uses patented TriCor 3D signal collection to synthesize a 12-lead ECG; 26 issued patents worldwide.
The HeartBeam System received FDA clearance for arrhythmia assessment in Dec 2024; 12-lead ECG synthesis software received clearance in Dec 2025.
FDA-cleared use is limited to arrhythmia assessment; heart attack detection, AI algorithms, patch and remote products are not cleared for sale.
Clinical evidence includes 1,000+ patients, 17 papers and presentations, 300+ users and 22,000+ recordings.
Commercial launch and offering
Multiple commercial agreements cover NY metro, Dallas, South Florida and Southern California; first orders shipped and initial patients onboarded in Q2 2026, with increasing order magnitude in Q3.
24/7 reader service, onboarding and customer success are live; the system is being integrated into new-patient intake at concierge practices.
Annual patient subscription includes equipment, routine recordings, unlimited automated arrhythmia reads estimated from end-2026, and credits for cardiologist interpretation in under 30 minutes.
Planned first-year post-launch features include telehealth, wearable integration, community features, AI wellness algorithms and physician assessments of interval trends.
Market and growth strategy
Addressable opportunity is presented as 50M+ at-risk patients and a $40B cardiac platform market, using a $750 annual patient spend assumption pending further validation.
Initial direct-pay entry targets 1.5M concierge and preventive cardiology patients, with a 3.5M broader patient-pay expansion opportunity.
June 2026 strategy shift prioritizes licensing the 3D ECG signal platform through established distribution channels, including health systems, ECG OEMs, monitor manufacturers and wearable companies.
Longer-term opportunity includes serving 50M+ patients across multiple applications and form factors, with partner and distribution discussions underway.
Latest events from Heartbeam
- Lower Q3 losses and FDA milestones advance heart-attack assessment, but funding risks remain.BEAT
Q3 2026 - Clinical and commercial progress accelerated, cash runway extended, but liquidity risks remain.BEAT
Q2 2026 - Directors and auditor approved; equity plan amendment failed; updates set for August.BEAT
AGM 2026 - Two board nominees, including the CEO, have withdrawn from re-election with no replacements named.BEAT
Proxy filing - Annual meeting to elect directors, ratify auditor, and expand equity plan by 3 million shares.BEAT
Proxy filing - FDA-cleared at-home 12-lead ECG platform targets $40B market with scalable, AI-driven growth.BEAT
Investor presentation - Annual meeting to elect directors, ratify auditor, and expand equity plan by 3 million shares.BEAT
Proxy filing - Net loss narrowed, cash burn fell, and $11.5M funding supports clinical and commercial growth.BEAT
Q1 2026 - AIMIGo nears FDA clearance as Q2 loss hits $5M, cash burn raises going concern risk.BEAT
Q2 2024